Firstword pharma news

Here are some recent pharma news updates:

1. Pfizer's COVID-19 Vaccine Shows 95% Efficacy in Final Trial Results

Pfizer and BioNTech have announced that their COVID-19 vaccine candidate, BNT162b2, has shown 95% efficacy in preventing severe illness and hospitalization due to COVID-19 in a final analysis of their Phase 3 clinical trial. (Source: Pfizer)

2. Novartis Acquires The Medicines Company for $9.7 Billion

Novartis has agreed to acquire The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases, for $9.7 billion. The deal is expected to strengthen Novartis' pipeline and expand its presence in the cardiovascular space. (Source: Novartis)

3. FDA Approves Gilead's Yescarta for Relapsed or Refractory Large B-Cell Lymphoma

The FDA has approved Gilead's Yescarta (axicabtagene ciloleucel), a CAR-T cell therapy, for the treatment of patients with relapsed or refractory large B-cell lymphoma. Yescarta is the first CAR-T cell therapy approved for this indication. (Source: Gilead)

4. AstraZeneca's Lynparza Shows Promise in Phase 3 Trial for BRCA-Mutated Breast Cancer

AstraZeneca has announced positive results from a Phase 3 trial of Lynparza (olaparib), a PARP inhibitor, in patients with BRCA-mutated breast cancer. The trial showed that Lynparza significantly improved progression-free survival compared to chemotherapy. (Source: AstraZeneca)

5. Johnson & Johnson's Imbruvica Receives FDA Approval for Waldenström Macroglobulinemia

The FDA has approved Johnson & Johnson's Imbruvica (ibrutinib), a BTK inhibitor, for the treatment of patients with Waldenström macroglobulinemia, a rare type of blood cancer. Imbruvica is already approved for several other blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma. (Source: Johnson & Johnson)

These are just a few of the latest pharma news updates. Let me know if you'd like me to provide more information or if you have any specific topics you'd like to explore!